Sturm E, Zech K
Biomed Mass Spectrom. 1984 May;11(5):211-6. doi: 10.1002/bms.1200110504.
The identification of biotransformation products of the new antihypertensive drug urapidil in mouse, rat, dog and man has been performed by means of high-performance liquid chromatographic and mass spectrometric techniques. In urine, three metabolites were found in addition to the unchanged drug. The para-hydroxylated product (1) (6-(3-[4-(o-methoxy-p-hydroxyphenyl)piperazinyl]-propylamino)-1, 3-dimethyl-uracil), the O-demethylated compound (2) (6-(3-[4-(o-hydroxyphenyl)piperazinyl]-propylamino)-1, 3-dimethyluracil) and the uracil-N-dealkylated compound (3) (6-(3-[4-(o-methoxyphenyl)piperazinyl]-propylamino)-1-methyluracil). In urine of dog, the metabolite with the N-oxide structure (5) was also identified, but only in trace amounts (6-(3-[4-(o-methoxyphenyl)piperazinyl-N-oxide]-propylamino)-1, 3-dimethyluracil).
已通过高效液相色谱和质谱技术对新型抗高血压药物乌拉地尔在小鼠、大鼠、犬和人体内的生物转化产物进行了鉴定。在尿液中,除了未变化的药物外,还发现了三种代谢物。对羟基化产物(1)(6-(3-[4-(邻甲氧基-对羟基苯基)哌嗪基]-丙基氨基)-1,3-二甲基-尿嘧啶)、O-去甲基化化合物(2)(6-(3-[4-(邻羟基苯基)哌嗪基]-丙基氨基)-1,3-二甲基尿嘧啶)和尿嘧啶-N-脱烷基化化合物(3)(6-(3-[4-(邻甲氧基苯基)哌嗪基]-丙基氨基)-1-甲基尿嘧啶)。在犬的尿液中,还鉴定出了具有N-氧化物结构的代谢物(5),但含量仅为痕量(6-(3-[4-(邻甲氧基苯基)-N-氧化物哌嗪基]-丙基氨基)-1,3-二甲基尿嘧啶)。